NCT05005819

Evaluation of [18F]APN-1607 as a PET Biomarker

Evaluation of [18F]APN-1607 as a PET Biomarker for Longitudinal Change in Tau Pathology in Participants With Progressive Supranuclear Palsy

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Invicro · Academic / Other
• Sex: All
• Age: 50 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The overall goal of this protocol is to evaluate \[18F\]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP.

Detailed description

The overall goal of this protocol is to evaluate \[18F\]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP. The specific objectives are: * To characterize and demonstrate the longitudinal progression of tau deposition in vivo in participants with PSP. * To determine optimal PET analysis parameters for \[18F\]APN-1607 quantification. * To characterize the stability of tau deposition in vivo over time in healthy volunteers (HVs). * To evaluate consistency of \[18F\]APN-1607 quantification in characterizing tau deposition.

Conditions

• Progressive Supranuclear Palsy
• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	[18F] APN-1607	Subjects will undergo PET imaging using \[18F\]APN-1607.

Timeline

• Start date: 2021-05-25
• Primary completion: 2024-01-09
• Completion: 2024-01-09
• First posted: 2021-08-16
• Last updated: 2025-02-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study